Archives
-
UTP Solution: From RNA Substrate to Assay Signal
2026-09-14
UTP Solution (100 mM) supports controlled RNA synthesis while helping researchers distinguish reagent performance from biological regulation. This article connects nucleotide handling to the TRIM66 olfactory receptor study and practical assay design across transcription, amplification, siRNA synthesis, and metabolism.
-
Atorvastatin: HMG-CoA Reductase Inhibitor Workflows
2026-09-14
Atorvastatin connects mevalonate-pathway inhibition with practical assays for cholesterol metabolism, vascular phenotypes, and ferroptosis-oriented cancer research. This workflow-focused guide covers dosing, controls, cross-domain interpretation, and troubleshooting for reproducible preclinical experiments.
-
Indometacin Sodium: From COX to Assay Design
2026-09-13
Indometacin Sodium is more than a conventional COX inhibitor: its salt chemistry, prostaglandin synthesis inhibition, and Wnt/β-catenin activity create a framework for better assay design. This guide connects clinical evidence with inflammation, pain-signaling, and remyelination research while clarifying dose translation and experimental limitations.
-
Mecamylamine Hydrochloride: Assay Design
2026-09-12
Mecamylamine hydrochloride provides a mechanistic tool for testing nicotinic contributions to gut-brain cholinergic signaling. This article translates recent Bacteroides fragilis epilepsy findings into practical assay decisions while defining the compound’s limits in neuropsychiatric disorder research.
-
Annexin V-Cy5 in Reversible Microglial Stress
2026-09-11
A translational framework for using Annexin V-Cy5 apoptosis detection to distinguish genuine cell death from reversible lysosomal dysfunction in microglial neuroimmunotoxicity models.
-
Ibrexafungerp Against Resistant Candida auris
2026-09-11
The reference study shows that ibrexafungerp, also known as MK 3118, retains consistent in vitro activity against fluconazole-resistant Candida auris and improves outcomes in a neutropenic mouse model when treatment is initiated after infection is established. Its combination of glucan-synthase targeting, oral administration, and activity in an invasive infection model supports further investigation against drug-resistant candidiasis, while the model design also defines important limits for clinical translation.
-
KN-62: Selective CaMKII Inhibitor Guide
2026-09-10
KN-62, also known as 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, is a research inhibitor of CaMKII with a reported Ki of 0.9 μM. Product data support applications in calcium signaling, secretion, glucose transport, and K562 cell-cycle studies, while the cited social-memory study provides biological context but does not test KN-62 directly.
-
Exendin-4 Workflows for Diabetes Research
2026-09-10
Build stronger beta-cell, cAMP, insulin-sensitivity, and hepatic-steatosis assays with Exendin-4, also known as Exenatide. This practical guide connects controlled peptide experiments with a 2024 yeast-expression strategy while separating validated findings from workflow recommendations.
-
Sabutoclax: Reliable Pan-Bcl-2 Assay Design
2026-09-09
This scenario-based guide shows how Sabutoclax (SKU A4199) can support more interpretable cell-viability, proliferation, and apoptosis experiments. It connects documented potency, formulation, and storage information with practical assay-design decisions while distinguishing growth inhibition from true cell killing.
-
DHEA at the Ovarian–Neural Research Interface
2026-09-09
Dehydroepiandrosterone (DHEA) is more than a steroid precursor: it is a context-dependent research perturbation that can reveal links among inflammation, granulosa cell fate, apoptosis, and neural survival. This thought-leadership guide shows how to use DHEA models strategically while separating mechanistic evidence from translational inference.
-
DNase I (RNase-free) for RNA Workflows
2026-09-08
DNase I (RNase-free) removes residual DNA without introducing RNase into RNA extraction, RT-PCR, or transcription workflows. Its ion-dependent cleavage behavior also supports chromatin and RNA:DNA hybrid applications, making it a practical cleanup step for sensitive self-amplifying RNA studies.
-
Lovastatin: HMG-CoA Reductase Inhibitor Guide
2026-09-08
Lovastatin is an HMG-CoA reductase inhibitor that blocks mevalonate production and alters cholesterol and isoprenoid biology. Product-reported benchmarks support applications in cancer research, mesangial-cell proliferation studies, fibroblast apoptosis, and macrophage efferocytosis, but assay-specific validation remains essential.
-
N1-Methylpseudouridine for mRNA Translation
2026-09-07
N1-Methylpseudouridine is a modified nucleoside for mRNA translation enhancement and protein-expression research. In a preprint study, codon optimization combined with N1-methylpseudouridine produced approximately 1,000-fold higher reporter potency than wild-type unmodified mRNA, while product data report high solvent solubility and reduced innate immune activation in several experimental systems.
-
WNT5A–KIF26B Degradation: Domain and GSK3 Control
2026-09-07
The reference study identifies a C-terminal degradation domain in KIF26B that is required for WNT5A-dependent protein turnover and shows that a disease-associated KIF26B mutation disrupts this response. Its flow cytometry-based reporter also provides a practical way to measure noncanonical WNT5A signaling in somatic and stem-cell contexts while implicating GSK3 as a regulatory component.
-
Catalpol Mechanisms in Alzheimer’s Disease
2026-09-05
The 2022 review by Chen and colleagues synthesizes preclinical evidence that Catalpol, also known as Catalpinoside in some contexts, may protect against Alzheimer’s disease through coordinated anti-inflammatory, antioxidant, antiapoptotic, cholinergic, and neurotrophic effects. Its main value is mechanistic integration: the review connects several cellular processes implicated in Alzheimer’s pathology while also highlighting the need for better-standardized disease models and clinical validation.